Dr. Johannes Backs has been appointed scientific director of the Helmholtz Institute for Translational AngioCardioScience (HI-TAC) as of October, 2026. The physician and former interim director shares the role with vascular biologist Dr. Karina Yaniv, who joined HI-TAC as scientific director in April 2026.
HI-TAC is a Helmholtz Institute jointly founded by the Max Delbrück Center and Heidelberg University and its medical faculties in Heidelberg and Mannheim. Along with HI-TAC’s junior groups, both Yaniv and Backs conduct research at both locations.
“In recent years, we’ve learned a lot about the central role the cardiovascular system plays in our health and in the development of diseases,” says Yaniv. “The next challenge is to translate this knowledge into better approaches to prevention, diagnosis, and treatment. Johannes is an ideal partner for tackling these challenges swiftly and collaboratively.”
Bridging discovery research and clinical translation
Backs, who holds a professorship at the Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), will continue to serve as director of the Institute for Experimental Cardiology at Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital. He will devote half his working hours to HI-TAC, the development of which he has supported from the very beginning.
“I’m excited to work with Karina to further investigate how the heart communicates with the vascular system and other organs. We aim to identify new therapeutic approaches not only for cardiovascular diseases, but also for age-related metabolic and brain disorders,” he says. “Together with the new HI-TAC junior research groups and collaborating institutions in Berlin, Heidelberg and Mannheim, we will also work to translate these discoveries into new treatments and bring them to patients as quickly as possible.”
From molecular mechansims to drug targets
Backs has identified several potential drug targets in recent years. For example, he discovered that in patients with a severe inherited heart condition, RBM20 cardiomyopathy, a signaling protein called CAMK2D is overactive. His team blocked the signaling pathway and was able to prevent the disease in mice. To translate this finding toward the clinic, he is collaborating with a small pharmaceutical company that has developed an inhibitor of CAMK2D and is currently testing it in clinical trials.
Backs’ research has also revealed an important signaling pathway in broken heart syndrome that causes the enzyme calcineurin to become overactive. The condition, which primarily affects women after menopause and can be triggered by emotional stress, leads to acute heart failure. His team has found that a drug already approved for another indication may prevent stress-induced heart failure. The drug is currently being investigated in a clinical trial at the DZHK.
In heart failure with preserved ejection fraction (HFpEF), a common form of heart failure, Backs identified an overactive enzyme called HDAC4, which he has been studying for more than 20 years. To improve treatment of HFpEF and other cardiovascular conditions, he has launched a startup. The company is preparing clinical trials to test inhibitors of HDAC4 and related enzymes.
How the heart communicates with other organs
At HI-TAC, Backs will focus on how the heart communicates with other organs. Specifically, he will study how heart muscle cells interact with the inner layer of blood vessels, endothelial cells and with blood platelets. Preliminary findings show that this interaction is what causes the heart to stiffen in HFpEF. “We want to find therapeutic targets outside heart cells that are easier for new drugs to reach,” says Backs.
He will also explore how the heart communicates with adipose tissue. “In a mouse model of HFpEF, we found that when we specifically inhibit HDAC4, not only does this strengthen the heart, but the animals also develop less inflamed adipose tissue and are less likely to become overweight,” Backs explains. “This points to new therapeutic targets for obesity.”
In another project, Backs will investigate how the brain and heart communicate during a stroke, especially how signals from the brain may trigger the heart’s stress response.
About Johannes Backs
Johannes Backs earned his doctorate in medicine at Heidelberg University. He later completed his clinical training in internal medicine at Heidelberg University Hospital and as a postdoctoral researcher in Dr. Eric N. Olson’s lab in the Department of Molecular Biology at the University of Texas Southwestern Medical Center. In 2007, he returned to Heidelberg University as an Emmy Noether Junior Research Group Leader funded by the German Research Foundation (DFG).
Today, Backs is Director of the Institute of Experimental Cardiology at Heidelberg University’s Medical Faculty and Heidelberg University Hospital, a professor at the DZHK, and spokesperson for the DFG-funded Collaborative Research Centre “Molecular Circuits of Heart Disease” at Heidelberg University. Backs has served as interim co-director of HI-TAC since 2024.
Source: Press release Max Delbrück Center
